|
|
 |
|
Viewing report
|
|
|
|
Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005
Bioseeker, April 2005
This is the second analytical tool to analyze the future competitive situation of breast cancer therapeutics. More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development. As new data is emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change. Replacing Tamoxifen, a selective estrogen receptor modulator that has been used for more than 20 years to treat patients with advanced breast cancer. Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval. A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales for the top three breast cancer hormone therapies on the market reaching more than $1.8 billion.
'Analytical Tool: Breast Cancer R&D: A Comprehensive Guide' is the ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Those who are victorious in the field plan effectively and change decisively. It provides a complete and systematic description and analysis of the past, present and future efforts in cancer R&D from both industry as well as academic. We have identified structured and defined information necessary to analyze the most candidates currently under development. Our included CD-ROM database contains thousands of records on the issue of R&D and collaborations derived from a multitude of sources, e.g. news releases, company sources, conferences, scientific publications, patents and published interviews etc.
This highly updated database reflects the most recent advances in the field. Enabling you to perform your own specific analysis, go back to the source data for in-depth information, and to offer you an opportunity to easily produce tables and graphs of the information suited for your own specific purposes.
Reasons to purchase this Analytical Tool:
- This is the only product that provides you with a complete structure of the areas involved in analyzing breast therapeutics.
- It identifies and structures most B2B collaborations and industry-academic alliances
- It covers close to all areas of cancer therapeutic strategies You will be able to study areas in conjunction to cancer structured by therapy type, drug effects, mechanisms/targets and combinatory therapies
- It enables you to track cutting edge competitive companies, therapies and technologies in the future market
- You will save time and money by rapid identification and analysis of competitors and business opportunities.
- You will be able to evaluate progress in both established as well as novel treatment strategies competing within the field of cancer drug development in big pharma.
This Analytical Tool includes three parts:
Breast Cancer: The Latest R&D Trends
Basic Platform Report: Breast Cancer
Business Development and R&D Database: Breast Cancer
Example of candidates included:
The complete number of candidate drugs in clinical research for breast cancer, are more than 150, and some of them below are listed below:
Abraxane, Alimta, Arimidex, Aromasin, Avastin, BMS-217380-01, BMS-247550, CAELYX, CCI-779, Faslodex, Femara, Fenretinide, Gleevec, GTI-2040, Herceptin, Iressa, ISIS-2503, Lapatinib, Nolvadex, Sarasar, SDX-105, Tarceva, Theratope Velcade, Zarnestra, Zoladex ZD0473 and many other that are in an earlier stage of development.
Customers who bought this item also bought
Breast Cancer Insight - Defining Drug Decisions - How Can Companies Influence the Treatment of Breast Cancer?
Analytical Tool: Cancer Vaccine
Strategic Perspectives 2001: Breast Cancer Cost Analysis
Drugs of Tommorow 2002: Breast Cancer
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Pipeline Insight: Breast Cancer - Complex Combinations of Old and New?
Stakeholder Insight: Breast Cancer Chemotherapy
Breast Cancer Opinion Leader Forum
|
|
|
|
